Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma
Status:
Recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of solriamfetol in improving sleep in patients
with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug. Giving solriamfetol
may improve sleep, memory, fatigue, mood, or quality of life in patients with brain tumors
(gliomas).